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Abstract
Background: Endometriosis is a well-known cause of infertility, and the anti-Mullerian hormone (AMH) is an
accepted biomarker of ovarian reserve and response to artificial reproductive technology procedures. The present
study was a prospective analysis of age-dependent AMH serum concentration in women with bilateral and
unilateral ovarian endometriomas before therapy onset compared with healthy controls.
Methods: This prospective cross-sectional study included 384 women aged 18–48 years. AMH serum concentration
was assessed between days 3 and 6 of the menstrual cycle in 78 patients with bilateral and 157 patients with
unilateral ovarian endometriomas and compared with 149 healthy controls. Ovarian endometriosis was confirmed
histopathologically, and data were presented as medians with interquartile range (IQR).
Results: Stage III endometriosis was diagnosed in 53.2 %, stage IV in 18.3 %, stage V in 23.4 % and stage VI in 5.4 %
of the patients. Patients with bilateral ovarian endometriomas showed the lowest median AMH levels compared
with patients suffering from unilateral ovarian endometriosis (0.55; IQR: 0.59 vs. 2.00; IQR: 2.80; p < 0.001) and the
control group (0.55; IQR: 0.59 vs. 2.84; IQR: 3.2; p < 0.001). Median AMH concentration values were not significantly
different between patients with unilateral ovarian endometriosis and the healthy controls (2.00; IQR: 2.80 vs. 2.84;
IQR: 3.2; p = 0.182). A strongly negative correlation between AMH levels and age was confirmed in healthy
individuals (R = −0.834; p < 0.001) and women with unilateral ovarian endometriomas (R = −0.774; p < 0.001).
Patients with bilateral ovarian endometriosis showed a significantly negative but only moderate correlation
between AMH levels and age (R = −0.633; p < 0.001), which was significantly lower than in the healthy controls
(R = −0.633 vs. R = −0.834; p = 0.006) but not in the patients with unilateral ovarian endometriosis (R = −0.663 vs.
R-0.774; p = 0.093). Based on a multivariate regression analysis, only bilateral localization of ovarian endometrial
cysts (p = 0.003) and patient age (p < 0.001), but not left/right localization of unilateral cyst or cyst volume, were
negatively associated with AMH serum concentration.
Conclusion: According to our data, unilateral ovarian endometriosis had a moderately negative and nonsignificant
effect on AMH-based ovarian reserve evaluated prior to surgery, irrespective of age. In contrast, the ovarian reserve
was significantly reduced in women with bilateral ovarian endometriomas.
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Background
Infertility is an increasing medical and socioeconomic
problem affecting up to 15 % of couples [1]. Fortunately,
many of these patients have an opportunity for parent-
ing, due to rapidly developing diagnostics and artificial
reproduction techniques (ARTs). Among many factors
responsible for fertility problems, endometriosis is often
recognized in women diagnosed with infertility [2].
Endometriosis affects up to 10 % of women of repro-
ductive age, and its pathogenesis, despite numerous
studies, has not been elucidated [3]. As many as 40 % of
patients with endometriosis will face fertility problems
[4], which can be caused by direct ovarian destruction,
impotence of fallopian tubes, due to intraperitoneal ad-
hesions or impaired follicle growth, and ovulation disor-
ders resulting from local pelvic inflammation [5]. Women
diagnosed with endometriosis suffer from endometrial
polyps and have a high rate of implantation failure [6].
Moreover, endometriomas may damage otherwise healthy
ovarian tissue. Hughesdon described the ovarian cortex
near an endometrioma as stretched and disorganized
with evidence of smooth muscle metaplasia [7]. Re-
cent studies have identified several toxic agents, such
as pro-inflammatory cytokines, reactive oxygen species
(ROS) and iron deposits in endometriotic fluid [8, 9].
Because the barrier separating cyst fluid from normal
ovarian tissue is 1 mm thick and composed of fibror-
eactive tissue and the ovarian cortex, endometriotic
fluid is thought to be highly harmful to the surround-
ing cells and the healthy ovarian cortex tissue near
the endometrioma. ROS and cytokines cause fibrosis
of the ovarian tissue and a reduction in cortex-specific
stromal cells [9]. Subsequently, the fibrosis together with
the ROS-triggered decrease in angiogenesis and capillary
loss in the ovarian cortex impair follicle nutrition and may
be responsible for lower follicular density and functional
follicle loss in the ovaries with endometriosis [10]. These
findings support the theory that endometriomas cause
ovarian damage before surgical treatment.
Many women with pelvic endometriosis and concomi-
tant infertility require ART procedures. However, patients
suffering from endometriosis have also been reported to
show a decreased ovarian reserve compared to healthy in-
dividuals of the same age [11, 12]. The evidence of endo-
metriosis was also proven to be a risk factor for a reduced
response to controlled ovarian stimulation in women
undergoing ART [13]. The anti-Mullerian hormone level
is a useful marker of the ovarian reserve and response
used in fertility therapy [14] and allows individualized
treatment, reducing clinical risk of ART-related complica-
tions and improving the pregnancy rate [15].
AMH was identified as a glycoprotein dimer com-
posed of two monomers of 72 kDa, each connected with
disulfide bridges and belongs to the transforming growth
factor β (TNFβ) family [16]. AMH is produced exclu-
sively by granulosa cells of ovarian follicles and may have
a regulatory effect on the axial folliculogenesis [17]. Ex-
periments in mice suggest that AMH inhibits the growth
of primary follicles and is involved in the growth regula-
tion of antral, preantral and small follicles by inhibiting
their sensitivity to follicle-stimulating hormone (FSH)
[18]. AMH secretion is strongly associated with age, with
production starting in the 36th week of fetal life and
reaching a peak in puberty before continuously decreas-
ing until menopause when often reaches undetectable
values [19, 20]. Many studies confirmed that AMH levels
decline with age in peripartum and in patients with se-
vere pelvic edometriosis but remains stable during the
menstrual cycle, which allows for its random determin-
ation irrespective of the cycle day [17, 21–24]. However,
Hadlow et al. reported variations in AMH serum con-
centration during the menstrual cycle with a gradual
decrease from the early-follicular to the late-luteal
phase of the menstrual cycle with peak values in the
mid-follicular phase [25].
AMH is an accepted biomarker of the ovarian reserve
and response to ART procedures; however, a lack of ref-
erence values established separately for female cohorts
with different ovarian pathology can be a major draw-
back in its clinical utility. Based on our literature review,
we hypothesize that endometriomas themselves can im-
pair ovarian reserve irrespective of surgical treatment.
To clear this hypothesis, we set up a prospective study
evaluating AMH levels in women with ovarian endomet-
riosis. The aim of the study was a preoperative evalu-
ation of serum AMH concentration in women with
unilateral and bilateral endometriomas, depending of the
ages of the patients.
Methods
All women referred to the Gynecology and Oncology
Department and Endocrine Gynecology Department of
the Jagiellonian University Medical College, Krakow,
from January 2009 to December 2014, were construct-
ively and prospectively evaluated for this study. Inclusion
criteria were age (18–48 years) and bilateral or unilateral
ovarian endometriosis diagnosed during laparoscopy or
laparotomy and confirmed histopathologically. We ex-
cluded the following subjects: (1) pregnant women; (2)
patients with previous excision of ovarian cysts; (3) pa-
tients diagnosed with infertility (unless solely related to
endometriosis or the male factor infertility); (4) patients
who had received hormonal treatment during the prior
36 months; (5) patients diagnosed with endocrine disor-
ders; (6) patients suffering from chronic disease (defined
as illness lasting 3 months or more, according to the
U.S. National Center for Health Statistics); and (7) pa-
tients with a history of malignancy. The control group
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consisted of healthy volunteers who participated in the
National Screening Program against Cervical Cancer.
Control group exclusion criteria included a history of (1)
infertility, (2) endometriosis, (3) early pregnancy loss, (4)
hormonal disorders, (5) malignancy, and (6) pelvic/
abdominal cavity surgery. All the participating women
signed an informed consent document, and the research
was approved by the Jagiellonian University Ethics Board
(KBET/21/B/2009).
Diagnostic procedures
Every woman meeting the inclusion criteria had her
medical history recorded and underwent a bimanual
pelvic examination by an experienced gynecology or
gynecologic endocrinology consultant. Subsequently, a
transvaginal ultrasonography was performed using a
Voluson 730 Pro equipped with a 6.5 MHz trans-vaginal
probe (General Electric Medical Systems, Kretztechnik,
Zipf, Austria) to evaluate the uterus and ovaries and look
for the presence of endometrial cysts. The volume of
each endometrial cyst was evaluated in every case and
expressed in cm3.
Surgical treatment
The majority of the patients (98.3 %) with an initial diag-
nosis of endometrial ovarian cysts underwent routine
unilateral/bilateral laparoscopic cyst enucleation and ex-
cision of peritoneal endometriosis. In three cases, a con-
version to laparotomy was performed due to severe
intraoperative bleeding (n = 1) and the need for partial
large bowel resection and anastomosis (n = 3). None of
the patients required hysterectomy or adnexectomy. The
bleeding was controlled by bipolar coagulation (85.5 %)
and ovarian suturing (14.5 %).
Histopathological examination: Although histopatho-
logical evaluation of endometriosis visualized during sur-
gery was not necessary to make the final diagnosis, all of
the excised specimens were examined postoperatively by
experienced pathologists using hematoxylin-eosin stain-
ing and immunohistochemistry, according to our routine
procedures. The postoperative diagnosis was based on
the final histopathological report confirming ovarian
endometriosis.
Blood analysis
Venous blood samples were analyzed between days 3
and 6 of the menstrual cycle to determine the AMH
levels. In patients with ovarian endometriomas, the aver-
age time between blood collection and surgery was 33
days (range 3–47 days) as the vast majority of women
were scheduled for operation during the next menstrual
cycle after blood collection. Immediately after collection,
the samples were centrifuged for 15 min at 1400 rpm.
The serum was aspirated and transferred to 1.5 mL
Eppendorf tubes and stored for up to 3 months at −80 °
C. Baseline blood samples were collected between days 3
and 7 of the menstrual cycle. The biochemical analysis
was performed using the enzyme-linked immunosorbent
assay (ELISA) method. The 96-well plates (Biokom) were
incubated with the blood serum (50 μL per well) for 12
h at 4 °C. Each plate was washed with 3 x 200 μL PBS
(pH 7.0) using an automatic scrubber. The plates were
re-incubated with the primary antibody at a dilution of
1:10,000 (Thermo Scientific) for 12 h at +4 °C. Next, the
plates were incubated for 2 h with secondary antibody
labeled with horseradish peroxidase (HRP) and a 15 min
incubation with 3,3′,5,5′-tetramethylbenzidine (TMB,
Thermo Scientific). Immediately after putting on the
stop solution (1 nM HCl, Thermo Scientific), the plates
were read using an ELISA reader with KC Junior
program. Measurements were performed in duplicate.
Standardization curves included 8 steps at the stage
r = 0.95. The serum AMH concentration was expressed
in ng/mL, and the functional detection limits ranged from
0.05 to 15.00 ng/mL.
Statistical analyses
The Kolmogorov-Smirnov test was used to evaluate the
distribution of variables. To compare the variables with
normal distribution, an analysis of variance (ANOVA)
test was performed, and the data were presented as the
mean values with standard deviation (SD). To analyze
continuous data with a different distribution than
normal and quantitive variables, a chi square test or
Kruskal-Wallis ANOVA was used, and baseline charac-
teristics were presented as median values with interquar-
tile range (IQR). Post hoc exploration (Fisher’s least
significant difference test) was performed if significant
differences were found during the ANOVA analysis.
Multiple regression was used to analyze the impact of
different clinical variables on the serum AMH level.
Because serum AMH concentration showed a skewed
distribution, logarithmic transformation was applied for
further testing. Spearman’s correlation test was used to
analyze the relationship between AMH serum level and
age, and the results were presented using Spearman’s
correlation index (R). A p-value of 0.05 was considered
to indicate statistical significance. All calculations were
performed using STATISTICA data analysis software,
version 10.0 (StatSoft, Inc. 2011, Tulsa, OK, USA).
Results
A total of 498 women were eligible for the study, and
235 fulfilled the inclusion criteria (78 women with bilat-
eral and 157 with unilateral and ovarian endometriomas;
Fig. 1). Among the patients with endometriosis, 68 were
part of a couple experiencing fertility problems, 86 had
pelvic pain syndrome (PPS), and 91 were diagnosed with
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ovarian endometriosis during a routine gynecological
examination and referred for further management. Male
factor infertility was diagnosed in 17 of the 68 infertile
pairs. In 51 couples, a comprehensive infertility examin-
ation revealed no potential causes of infertility apart
from the presence of endometriomas. These women
were diagnosed with endometriosis-related infertility
and included in the study. The control group consisted
of 149 women with no gynecological disorders, a history
of pelvic/abdominal surgery, pregnancy or chronic diseases
and who attended cervical cancer screening programs.
More than half of the patients (53.2 %) suffering from
endometriosis were diagnosed with stage III disease ac-
cording to the European Society of Human Reproduction
and Embryology (ESHRE) criteria [26]. Stage IV endomet-
riosis was recognized in 18.3 % of women, and stages V
and VI were confirmed in 23.4 % and 51 %, respectively.
There were no cases of stage I-II endometriosis because
such patients do not present with an ovarian mass. In pa-
tients with unilaterality, ovarian endometrial cysts were
predominantly localized in the right ovary (Table 1). There
were no differences in ovarian endometrioma volume be-
tween patients with bilateral and unilateral ovarian mass
(Table 1). Women with bilateral and unilateral ovarian
endometriosis suffered significantly more frequently with
painful and irregular menstruation compared to healthy
women (Table 1). Patients suffering from bilateral but not
unilateral ovarian endometriomas presented significantly
lower gravidity (p < 0.001) and parity (p = 0.003) com-
pared to the control group. No significant differences in
median age, median age of first period, body mass index
(BMI) or amount of menstrual discharge were noticed be-
tween the groups analyzed (Table 1).
Patients with bilateral ovarian endometriomas pre-
sented the lowest median AMH levels, compared to
women suffering from unilateral ovarian endometri-
osis (0.55; IQR: 0.59 vs. 2.00; IQR: 2.80; p < 0,001)
and the control group (0.55; IQR: 0.59 vs. 2.84; IQR:
3.2; p < 0.001). Patients with ovarian unilateral endo-
metriosis also showed lower but insignificant median
AMH levels compared to the control group (2.00; IQR:
2.80 vs. 2.84; IQR: 3.2; p = 0.182). Based on multivariate
regression, only bilateral localization of ovarian endo-
metrial cyst (p = 0.003) and patient age (p < 0.001) but
not localization or cyst volume were negatively associ-
ated with the AMH serum concentration.
Eligible patients n=498
Excluded patients n=263
- pregnancy  (n=9)
- history of ovarian surgery (n=45)
- infertility (not related to 
endometriosis) (n=23)
- treated with hormones during the 
past 36 months (n=31)
- with endocrine disorders  (n=66)
- with chronic diseases (n=51) 
- with history of malignancy (n=5)
- lack of AMH evaluation (n=19)
- age over 48 years (n=14)
Recruited patients: total n = 235
Bilateral ovarian 
endometriosis n=78
Healthy individuals
n=149
Unilateral ovarian 
endometriosis n=157
Total number of included women: total n =384
Fig. 1 Flow diagram demonstrating the patient recruitment procedure
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An age-related decrease in AMH levels was confirmed
in the control group and in patients with unilateral and
bilateral ovarian endometriomas (Fig. 2).
A strong negative correlation between AMH levels and
age was confirmed in the healthy controls (R = −0.834;
p < 0.001) and women with unilateral ovarian endomet-
riosis (R = −0.774; p < 0.001). In women with bilateral
ovarian endometriosis, a moderately negative correlation
between AMH levels and age was observed (R = −0.663;
p < 0.001). Correlation indices for AMH levels and age
Table 1 The clinical characteristics of patients with bilateral and unilateral ovarian endometrioas and the healthy women
Patients with bilateral ovarian
endometrimas (n = 78)
Patients with unilateral ovarian
endometrimas (n = 157)
Healthy controls
(n = 149)
p
Median age [yers] (IQRb) 35,50 (17,00) 32,00 (15,00) 32,00 (18,00) NSc
Mean BMI [kg/m2] (±SDa) 22,72 (±1,61) 23,19 (±2,13) 23,41 (±2,51) NSc
Endometrial cyst localization
Right ovary 78 (100,00 %) 93 (59,23 %) NAe NAe
Left ovary 78 (100,00 %) 64 (40,77 %)
Mean volume of ovarian endometriomas [cm3] 6,23 (±1,12) 6,41 (±1,18) NAe NSc
Mean age of first menstrual period [years] (±SDa) 11,52 (±1,52) 11,38 (±1,64) 11,45 (±1,81) NSc
Mean duration of menstrual cycle [days] (±SDa) 28,50 (±2,5) 29,50 (±3,0) 28,00 (±2,0) NSc
Menstrual cycles 42 (53,85 %) / 116 (73,89 %) / 124 (83,22) / <0,001d
Regular/Irregular 36 (46,15 %) 41 (26,11 %) 25 (16,78 %)
Menstrual cycles 38 (48,72) / 42 (26,75 %) / 32 (21,48) / <0,001d
Painful/painless 40 (51,28 %) 115 (73,25 %) 117 (78,52 %)
Mean duration of menstruation [days] 4,25 (±1,52) 4,12 (±1,31) 4,32 (±0,97) NSc
Type of menstrual bleeding NSc
Scant 7 (11,54 %) 12 (7,64 %) 8 (10,69 %)
Normal 52 (66,67 %) 115 (73,25 %) 117 (75,52 %)
Heavy 17 (21,79 %) 30 (19,11 %) 24 (13,79 %)
Median number of gestations (IQRb) 1,0 (1,0) 2 (2) 3 (2) 0,028d
Median number of deliveries (IQRb) 0,5 (1) 2 (1) 3 (1) 0,016d
aSD – standard deviation; bIQR – interquarlite range; cNS – statistically not significant; dstatistically significant value; eNA – data not available
Fig. 2 Age-related anti-Mullerian hormone (AMH) distribution in patients with bilateral ovarian endometriomas, unilateral ovarian endometriomas
and the controls
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did not differ significantly between women with unilateral
endometriosis and the controls (R = −0.774 vs. R = −0.834;
p = 0.140). However, patients with bilateral ovarian endo-
metriomas showed a significantly weaker correlation
between AMH levels and age compared to the con-
trols (R = −0.633 vs. R = −0.834; p = 0.006) but
not the patients with unilateral ovarian endometri-
osis (R = −0.663 vs. R = −0.774; p = 0.093).
For further analysis of AMH serum level, participants
were divided according to age into the following 6
groups: 18–22, 23–27, 28–32, 33–37, 38–42 and 43–48
years. Serum AMH levels were then evaluated in
patients with bilateral and unilateral ovarian endome-
triomas and compared to healthy controls in the same
age-related groups. In all age groups, serum AMH con-
centration was the highest in healthy controls. However,
in women aged 43 years and above, no significant differ-
ences in AMH levels were observed between patients
with bilateral ovarian endometriomas, unilateral ovarian
endometriomas and controls. In young women aged
18–22 years, we observed significantly lower median
AMH levels in patients with bilateral ovarian endo-
metriomas compared to the controls (0.82; IQR: 1.12
vs. 4.63; IQR: 1.09; p < 0.001) and between patients
with bilateral ovarian endometriosis and unilateral
ovarian endometriosis (0.82; IQR: 1.12 vs. 4.24; IQR:
1.24; p = 0.036), while differences were not observed
between unilateral ovarian endometriosis patients and
the controls (4.24; IQR: 1.12 vs. 4.63; IQR: 1.09; p < 0.001;
Fig. 3). Additionally, women aged 23–27 years with bilat-
eral ovarian endometriomas showed significantly lower
median serum AMH concentrations compared to patients
with unilateral ovarian endometriomas (0.55; IQR: 1.07 vs.
4.10; IQR: 1.17; p < 0.001) and to controls (0.55; IQR: 1.07
vs. 4.24; IQR: 0.44; p < 0.001), while no significant differ-
ences in median AMH levels were found between unilat-
eral ovarian endometrioma patients and the healthy
controls (Fig. 3). Similar to previous groups in women
aged 28–32 years, patients with bilateral ovarian endome-
triomas showed the lowest median AMH serum levels
compared to women with unilateral ovarian involvement
(0.95; IQR: 0.37 vs. 2.25; IQR: 1.02; p = 0.001) and healthy
controls (0.95; IQR: 0.37 vs. 3.00; IQR: 1.86; p < 0.001),
with no significant differences observed between unilateral
ovarian endometriomas and the healthy controls (Fig. 3).
In women aged 33–37 years, the lowest median AMH
concentration was observed in patients with bilateral ovar-
ian endometriomas compared to patients with unilateral
ovarian endometriomas (0.49; IQR: 0.45 vs. 1.75; IQR:
0.38; p < 0.001) and controls (0.49; IQR: 0.45 vs. 1.98; IQR:
0.84; p < 0.001; Fig. 3). Additionally, in women aged
38–42 years, the significantly lowest median serum
AMH concentration was in patients with bilateral
ovarian endometriomas compared to patients with
unilateral ovarian endometriomas (0.35; IQR: 0.30 vs.
1.05; IQR: 0.70; p < 0.001) and the controls (0.35;
IQR: 0.30 vs. 1.35; IQR: 0.90; p < 0.001; Fig. 3). In
contrast to younger patients, women aged 43–48
years showed no statistically significant differences in
the median AMH concentration between women with
bilateral ovarian endometriomas (0.18; IQR: 0.19),
unilateral ovarian endometriomas (0.14; IQR: 0.78)
and the controls (0.49; IQR: 0.8; Fig. 3).
Discussion
In our study, we confirmed a significant age-related
AMH decrease in healthy women and patients with
ovarian endometriomas, both bilateral and unilateral,
18-22 23-27 28-32 33-37 38-42 43-48
Age groups [years]
0
1
2
3
4
5
6
7
A
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M
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H
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m
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A
M
H
) 
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l [
ng
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 1. Bilateral ovarian endometriomas
 2 Unilateral ovarian endometriomas
 3. Controlsp =0,036
p <0,001 p*<0,001
p*<0,001
p*<0,001
p*=0,001
p*<0,001
p*<0,001
p*<0,001
p <0,001*
*
*
Fig. 3 Differences in serum anti-Mullerian hormone (AMH) concentration levels between patients with bilateral and unilateral ovarian endometrio-
mas compared to healthy individuals in different age groups. *statistical significance at p < 0.05
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before the onset of surgical therapy [27–30]. Patients
with unilateral ovarian endometriosis showed a signifi-
cantly negative correlation between serum AMH level
and age. Correlation indices were not significantly differ-
ent between these patients and the healthy controls. On
the contrary, patients with bilateral endometriomas
showed a significantly weaker correlation between AMH
levels and age, which differed significantly from pa-
tients with unilateral endometriomas. Moreover, pa-
tients under 43 years of age with bilateral ovarian
endometriosis showed significantly lower serum AMH
concentration compared to patients with unilateral
ovarian endometriosis and healthy controls. The vast
majority of our participants were diagnosed with
moderate endometriosis, and only a few with a severe
disease. Interestingly Shebl et al. reported significant
differences in AMH levels between patients with severe
endometriosis and healthy individuals, while patients with
mild endometriosis showed AMH serum concentration
comparable to healthy controls [27]. Similar to our find-
ings, Somigliana et al., showed that only patients with bi-
lateral ovarian benign tumors (of which 72 % were
endometrial cysts) had significantly lower AMH serum
levels when compared to patients with unilateral ovarian
cysts and healthy women [31]. These results were again
confirmed in other studies showing no differences in
serum AMH levels between patients with mild endometri-
osis and healthy women [32–34]. Thus, unilateral endo-
metriosis negatively affects ovarian reserve although not
to statistical significance, while bilateral ovarian endome-
triomas result in significantly decreased AMH levels from
an early age. In women with unilateral ovarian endomet-
rial cysts, procreative ovarian function is sustained and
comparable to that of healthy individuals.
Lind et al. investigated AMH levels in women who
underwent surgery for benign ovarian tumors and found
that the reduction in AMH levels depended on the
histological type of the ovarian cyst and preoperative
AMH levels [35]. Somigalina et al. reported that presur-
gical AMH serum concentrations were higher in patients
with dermoid cysts than in women with endometriomas;
however, the difference was not statistically significant
[31]. These clinical findings are consistent with the path-
ology of endometriotic and non-endometriotic ovarian
cysts. Neither dermoid cysts nor simple ovarian cysts
cause local inflammation. Thus, healthy ovarian cortical
tissue surrounding a non-endometriotic cyst is not ex-
posed to pro-inflammatory agents or ROS, which are
present in endometriotic fluid. Furthermore, in contrast
to endometriomas, non-endometriotic ovarian cysts do
not contain iron deposits, which cause the hemosiderin-
laden macrophages that trigger follicular destruction in
the surrounding cortical tissue. Thus, it appears that
dermoid and simple ovarian cysts do not directly impair
ovarian function. Nevertheless, it must be emphasized
that surgical intervention and ovarian cystectomy for
benign ovarian tumors are independent risk factors for
reduced ovarian reserves.
Ovarian endometrial cysts may be directly responsible
for a decrease in AMH levels. However, surgical treat-
ment of endometriomas may be an additional and inde-
pendent risk factor for impaired ovarian function.
Several studies have investigated the impact of surgery
on ovarian function in women with endometriosis. Inter-
estingly, Streuli et al. reported that decreased serum
AMH levels in women with endometriosis were limited
only to those with previous endometrioma surgery [36].
Moreover, in patients undergoing laparoscopic cystec-
tomy due to ovarian endometriosis, a significant reduc-
tion in AMH secretion was reported [33]. Women with
higher preoperative AMH levels showed a more rapid
decrease in AMH levels. Similarly, in patients with uni-
lateral ovarian endometrioma, the decrease in AMH
levels was more significant and lasted longer compared
to women who underwent surgery for dermoid cysts
[35]. In contrast, Vignali et al. reported that the postop-
erative decrease in AMH levels in women who had
undergone laparoscopic excision of ovarian endometrial
cysts was temporary; AMH levels returned to preopera-
tive values 12 months after surgery [37]. Angioni et al.
investigated the feasibility of single-port access laparos-
copy (SPAL) compared with multiport laparoscopy
(MPL) for cystectomy of ovarian endometriomas [38].
Over a 3-month follow-up period, they observed a sig-
nificant decrease in AMH serum concentrations and an-
tral follicle count after SPAL compared with MPL and
concluded that SPAL cystectomy should not be recom-
mended for women with endometriomas who desire
pregnancy [38]. However, in addition to surgical access,
the cyst extirpation method and bleeding control can in-
fluence ovarian reserve. Although excisional surgery is
the gold standard treatment for endometriotic cysts, it
may result in unintended removal of healthy ovarian tis-
sue. Moreover, the use of bipolar coagulation to control
bleeding may damage healthy ovarian tissue, causing a
decrease in ovarian reserve. Nappi et al. found that laser
hemostasis using a dual-wavelength system did not
significantly reduce ovarian reserve and prevented fol-
licular loss after endometrioma surgery [39]. Thus, laser
hemostasis may be a better choice than bipolar coagula-
tion for women with endometriomas who wish to pre-
serve fertility. Many studies were in accordance with our
findings that unilateral ovarian endometriosis, which is
considered to be a moderate endometriosis according to
ESHRE criteria, does not impair ovarian procreation
function at any age.
As the procreative function of ovaries declines rapidly
after 35 years of age, we analyzed the association between
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age and AMH levels after stratification of patients accord-
ing to age. Serum AMH levels were significantly lower in
women with bilateral ovarian endometriosis who were
under 43 years of age than in age-matched patients with
unilateral endometriomas and healthy individuals. How-
ever, in women over the age of 42 years, no differences in
median serum AMH concentration was observed between
patients with bilateral or unilateral ovarian endometriosis
and the controls. This result can be explained because
after the age of 40 years, ovarian follicle function has de-
creased to the extent that endometriosis does not further
reduce ovarian reserve.
To our knowledge, this is the first comprehensive
study evaluating the relationship between serum AMH
concentration levels and age in women with bilateral
and unilateral ovarian endometriomas prior to surgery.
All laboratory evaluations were performed in one setting
by staff highly experienced in blood collection for serum
AMH level assessment, performed at a narrow point in
time to reduce research bias. However, this study had
several limitations. The primary limitation was the low
number of patients with bilateral ovarian endometrio-
mas. Second, women with incidental endometriomas
and PPS who experienced irregular periods were not
evaluated to identify the cause of menstruation irregular-
ity. Thus, it is possible that undiagnosed disorders were
the cause of impaired ovarian function in these women.
However, this potential bias was significantly mitigated
by an extensive review of available medical records and
histories to detect risk factors for impaired ovarian func-
tion apart from endometriosis, although the presence of
an undiagnosed disorder could not be completely ruled
out. The results obtained should be externally validated
in a larger cohort to gain an epidemiological impact.
Only a prospective follow-up of AMH secretion in
women with ovarian endometriomas conducted in a
large population and with age-matched controls over a
longer period of time will allow us to fully elucidate its
clinical utility.
Conclusions
In the present study, we showed a significantly negative
correlation between serum AMH concentration and age
in women with bilateral and unilateral ovarian endometri-
osis. However, median serum AMH levels were signifi-
cantly lower only in patients with bilateral ovarian
endometriomas compared to controls, while in patients
with unilateral ovarian endometriomas, median serum
AMH concentration was insignificantly lower compared
to the healthy individuals. According to our data, unilat-
eral ovarian endometriosis moderately impaired AMH-
based ovarian reserve prior to surgery, irrespective of age.
In contrast, in women with bilateral ovarian endometrio-
mas, a significant reduction in ovarian reserve was shown.
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